Upstream Support for New Drug R&D: How Biological Reagents and Laboratory Tools Influence Early Development

Upstream tool positioning in the new drug R&D chain

New drug research and development generally covers target discovery and validation, pilot compound screening, preclinical safety and efficacy evaluation, clinical trials, and post-marketing studies.Whether it is a small molecule chemical drug, a recombinant protein drug or a nucleic acid drug, protein expression, cell culture, gene editing, immunoassay, molecular diagnosis and other links at the laboratory stage are inseparable from biological reagents, cell lines, recombinant proteins, antibodies, molecular enzymes and related consumables.The upstream tool itself does not directly become a drug, but its performance and stability will directly affect the reproducibility of the experimental results and R&D decisions.

In early target validation, researchers typically use gene editing tools to build cell models by mimicking ligand-receptor binding with recombinant proteins, and analyze gene expression changes by fluorescent quantitative PCR or sequencing reagents.If there is a difference between batches or low activity of the reagent, it may cause fluctuations in the screening signal and increase the cost of repeated experiments.Therefore, the new drug R&D team is paying more and more attention to the traceability and quality consistency of upstream tools.

Common requirements for reagent performance for early screening

During the drug screening phase, reagents need to meet certain performance indicators, common concerns include purity, activity, endotoxin levels, host cell protein residues, nuclease contamination, and interbatch consistency.Taking the cell-based screening model as an example, the difference in the components of the medium and the serum substitute may change the cell growth state, which in turn affects the judgment of the activity of the compound.